Shares of UiPath Inc. (NYSE:PATH – Get Free Report) have received an average recommendation of “Hold” from the eighteen research firms that are currently covering the stock, MarketBeat reports. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.47.
PATH has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Wednesday, October 23rd. Wells Fargo & Company dropped their price target on UiPath from $15.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. TD Cowen decreased their price objective on UiPath from $17.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Bank of America raised their target price on shares of UiPath from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, September 6th. Finally, DA Davidson upped their price target on shares of UiPath from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Friday, September 6th.
Check Out Our Latest Analysis on PATH
UiPath Trading Down 0.8 %
UiPath (NYSE:PATH – Get Free Report) last issued its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.09) earnings per share. Research analysts anticipate that UiPath will post -0.23 EPS for the current fiscal year.
Insider Activity
In related news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the transaction, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.37% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On UiPath
Hedge funds have recently bought and sold shares of the company. Future Financial Wealth Managment LLC acquired a new stake in UiPath during the 3rd quarter valued at $26,000. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of UiPath during the 3rd quarter worth about $26,000. ORG Partners LLC boosted its holdings in shares of UiPath by 875.6% during the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after buying an additional 1,112 shares during the period. Hantz Financial Services Inc. acquired a new position in UiPath in the 2nd quarter valued at about $28,000. Finally, Redwood Wealth Management Group LLC bought a new position in UiPath in the 2nd quarter valued at about $43,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.
About UiPath
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Stories
- Five stocks we like better than UiPath
- What Is WallStreetBets and What Stocks Are They Targeting?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Learn Technical Analysis Skills to Master the Stock Market
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Why Are These Companies Considered Blue Chips?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.